PH12020551076A1 - Methods for treating diabetes, hepatitis, and/or inflammatory liver disease - Google Patents
Methods for treating diabetes, hepatitis, and/or inflammatory liver diseaseInfo
- Publication number
- PH12020551076A1 PH12020551076A1 PH12020551076A PH12020551076A PH12020551076A1 PH 12020551076 A1 PH12020551076 A1 PH 12020551076A1 PH 12020551076 A PH12020551076 A PH 12020551076A PH 12020551076 A PH12020551076 A PH 12020551076A PH 12020551076 A1 PH12020551076 A1 PH 12020551076A1
- Authority
- PH
- Philippines
- Prior art keywords
- hepatitis
- liver disease
- methods
- inflammatory liver
- treating diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862618332P | 2018-01-17 | 2018-01-17 | |
| PCT/US2019/013934 WO2019143767A1 (en) | 2018-01-17 | 2019-01-17 | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020551076A1 true PH12020551076A1 (en) | 2021-08-16 |
Family
ID=65324621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020551076A PH12020551076A1 (en) | 2018-01-17 | 2020-07-14 | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11866488B2 (https=) |
| EP (2) | EP4596042A3 (https=) |
| JP (2) | JP7486423B2 (https=) |
| KR (2) | KR102937161B1 (https=) |
| CN (2) | CN120267797A (https=) |
| AU (2) | AU2019209491B2 (https=) |
| BR (1) | BR112020014346A2 (https=) |
| CA (1) | CA3088661A1 (https=) |
| EA (1) | EA202091533A1 (https=) |
| ES (1) | ES3033317T3 (https=) |
| HR (1) | HRP20250727T1 (https=) |
| HU (1) | HUE072418T2 (https=) |
| IL (2) | IL316486A (https=) |
| MX (1) | MX2020007384A (https=) |
| PH (1) | PH12020551076A1 (https=) |
| PL (1) | PL3740282T3 (https=) |
| RS (1) | RS66918B1 (https=) |
| SG (1) | SG11202006421RA (https=) |
| SM (1) | SMT202500233T1 (https=) |
| WO (1) | WO2019143767A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020234718A1 (en) | 2019-03-13 | 2023-05-18 | Tearsolutions, Inc. | Compositions and methods for promoting islet viability and enhancing insulin secretion |
| EP3999531A1 (en) * | 2019-07-15 | 2022-05-25 | University of Connecticut | Metallothionein antibodies and their use |
| CN110551726B (zh) * | 2019-09-06 | 2021-04-09 | 上海市肺科医院 | 一种结核杆菌阿拉伯半乳聚糖适配子及其应用 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| KR102191405B1 (ko) * | 2020-09-15 | 2020-12-16 | 주식회사 에이스바이오메드 | 간 질환 예방 또는 치료용 조성물 |
| CN115317502B (zh) * | 2021-12-21 | 2023-07-07 | 青岛市市立医院 | 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用 |
| WO2025226837A1 (en) * | 2024-04-24 | 2025-10-30 | University Of Connecticut | Anti-bacterial metallothionein antibodies and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20030007973A1 (en) | 2001-06-22 | 2003-01-09 | Lynes Michael A. | Methods and compositions for manipulation of the immune response using anti-metallothionein antibody |
| CA2658673A1 (en) | 2005-07-27 | 2008-02-01 | Gerald J. Prud'homme | Composition and method for prevention and treatment of type i and type ii diabetes |
| WO2011050052A2 (en) * | 2009-10-20 | 2011-04-28 | Georgia State University Research Foundation, Inc. | Protein agent for diabetes treatment and beta cell imaging |
| CA2813711A1 (en) | 2010-10-14 | 2012-04-19 | Immunahr Ab | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
| CA2840282C (en) | 2011-07-08 | 2018-11-13 | Universiteit Gent | Use of antagonists targeting metallothionein to treat intestinal inflammation |
| WO2014172606A1 (en) * | 2013-04-19 | 2014-10-23 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
| TR201402685A1 (tr) | 2014-03-06 | 2015-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vildagliptinin farmasotik formulasyonları. |
| EP3149049B1 (en) * | 2014-05-27 | 2022-10-26 | The University Of Queensland | Il-22 for use in treating metabolic disorders |
| TW201613949A (en) | 2014-08-07 | 2016-04-16 | Regulus Therapeutics Inc | Targeting microRNAs for metabolic disorders |
-
2019
- 2019-01-17 MX MX2020007384A patent/MX2020007384A/es unknown
- 2019-01-17 SG SG11202006421RA patent/SG11202006421RA/en unknown
- 2019-01-17 CA CA3088661A patent/CA3088661A1/en active Pending
- 2019-01-17 RS RS20250601A patent/RS66918B1/sr unknown
- 2019-01-17 KR KR1020207022117A patent/KR102937161B1/ko active Active
- 2019-01-17 JP JP2020537722A patent/JP7486423B2/ja active Active
- 2019-01-17 ES ES19703874T patent/ES3033317T3/es active Active
- 2019-01-17 WO PCT/US2019/013934 patent/WO2019143767A1/en not_active Ceased
- 2019-01-17 HU HUE19703874A patent/HUE072418T2/hu unknown
- 2019-01-17 IL IL316486A patent/IL316486A/en unknown
- 2019-01-17 EA EA202091533A patent/EA202091533A1/ru unknown
- 2019-01-17 SM SM20250233T patent/SMT202500233T1/it unknown
- 2019-01-17 CN CN202510512846.1A patent/CN120267797A/zh active Pending
- 2019-01-17 PL PL19703874.8T patent/PL3740282T3/pl unknown
- 2019-01-17 IL IL276097A patent/IL276097B2/en unknown
- 2019-01-17 US US16/961,327 patent/US11866488B2/en active Active
- 2019-01-17 AU AU2019209491A patent/AU2019209491B2/en active Active
- 2019-01-17 EP EP25158063.5A patent/EP4596042A3/en active Pending
- 2019-01-17 EP EP19703874.8A patent/EP3740282B1/en active Active
- 2019-01-17 KR KR1020267006914A patent/KR20260042289A/ko active Pending
- 2019-01-17 CN CN201980008316.6A patent/CN111801140B/zh active Active
- 2019-01-17 HR HRP20250727TT patent/HRP20250727T1/hr unknown
- 2019-01-17 BR BR112020014346-4A patent/BR112020014346A2/pt unknown
-
2020
- 2020-07-14 PH PH12020551076A patent/PH12020551076A1/en unknown
-
2022
- 2022-08-12 AU AU2022215285A patent/AU2022215285B2/en active Active
-
2023
- 2023-07-24 US US18/357,632 patent/US12583916B2/en active Active
- 2023-10-27 US US18/496,279 patent/US20240067710A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002422A patent/JP2024028454A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551076A1 (en) | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
| MX2020010369A (es) | Particulas implantables y metodos relacionados. | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| PH12019500214A1 (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| EP4233910A3 (en) | Methods of treatment of cholestatic diseases | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| TW200716612A (en) | Pyrimidine compounds | |
| EP4338804A3 (en) | Epinephrine spray formulations | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| MY181928A (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| MX2020011099A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| JOP20190262B1 (ar) | مثبطات بيرازول magl | |
| MX2022002418A (es) | Composiciones y metodos de tratamiento de enfermedades vasculares. | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
| MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
| BR112012006070A2 (pt) | composições e métodos para tratar distúrbios convulsivos. | |
| PH12020500339A1 (en) | Novel compounds |